Pfizer drug causes weight loss similar to that of Ozempic – 05/22/2023 – Health
[ad_1]
Pfizer’s diabetes drug resulted in weight loss similar to Novo Nordisk’s Ozempic in an intermediate-phase study in patients with type 2 diabetes, according to data published in a medical journal.
Pfizer shares rose about 4.5% after the news, at a time of heightened interest from investors in the weight loss treatments market, which is expected to reach $100 billion (almost R$500 billion) by the end of the decade.
Pfizer’s danuglipron, when given twice daily, reduced blood sugar levels in patients at all doses and reduced body weight at the highest dose after 16 weeks compared with placebo, according to mid-phase data published last year by the North American pharmaceutical company.
The study evaluated 411 adults with type 2 diabetes, who received either the drug or a placebo.
Weight loss with danuglipron is of similar magnitude to that seen in mid-phase data for Novo Nordisk’s semaglutide, known as Ozempic when used for diabetes and Wegovy for obesity.
Ozempic was first approved in 2017 for diabetes and Wegovy in 2021 in the US for weight loss.
The treatments, including Pfizer’s danuglipron, are part of a class of drugs that mimic the gut hormone glucagon-like peptide-1 (GLP-1), which works by suppressing appetite and was initially developed to treat type 2 diabetes.
[ad_2]
Source link
